Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson’s Disease: A Systematic Review of Observational Studies | Zendy

Tanja Tran | Zendy; James M. Brophy | Zendy; Samy Suissa | Zendy; Christel Renoux | Zendy

Open Access

Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson’s Disease: A Systematic Review of Observational Studies

Author(s) -

Tanja Tran,

James M. Brophy,

Samy Suissa,

Christel Renoux

Publication year - 2015

Publication title -

cns drugs

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.565

H-Index - 108

eISSN - 1179-1934

pISSN - 1172-7047

DOI - 10.1007/s40263-015-0293-4

Subject(s) - medicine , cabergoline , valvular heart disease , hazard ratio , cohort study , pergolide , cohort , heart failure , observational study , dopamine agonist , confidence interval , dopamine , prolactin , dopaminergic , hormone

Dopamine agonists (DAs) are commonly used in the therapy of Parkinson's disease (PD). However, several observational studies have suggested a putative association between DAs and specific cardiac adverse events.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research